Patents by Inventor David Novack
David Novack has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12569553Abstract: The present disclosure relates to immunogenic compositions comprising a varicella zoster vims (VZV) glycoprotein E antigen and a toll-like receptor 9 (TLR9) agonist, such as an oligonucleotide comprising an unmethylated cytidine-phospho-guanosine (CpG) motif. The immunogenic compositions are suitable for stimulating an immune response against VZV in an individual in need thereof.Type: GrantFiled: March 9, 2021Date of Patent: March 10, 2026Assignee: Dynavax Technologies CorporationInventors: John D. Campbell, Randall N. Hyer, Robert S. Janssen, David Novack
-
Publication number: 20250360190Abstract: The present disclosure relates to immunogenic compositions comprising at least one Yersinia pestis (Y. pestis) antigen, an aluminum salt adjuvant, and an oligonucleotide comprising an unmethylated cytidine-phospho-guanosine (CpG) motif. The immunogenic compositions are suitable for stimulating an immune response against Y. pestis in a subject in need thereof. The present disclosure also relates to kits and methods using the immunogenic compositions, or two separate compositions which together comprise the antigen, the aluminum salt adjuvant, and the oligonucleotide.Type: ApplicationFiled: June 16, 2025Publication date: November 27, 2025Applicants: Dynavax Technologies Corporation, The Government of the United States, as Represented by the Secretary of the ArmyInventors: Robert S. JANSSEN, David NOVACK, Wai Kwan CHUNG, Andrew M. GLENN, Lucy A. WARD
-
Patent number: 12364745Abstract: The present disclosure relates to immunogenic compositions comprising at least one Yersinia pestis (Y. pestis) antigen, an aluminum salt adjuvant, and an oligonucleotide comprising an unmethylated cytidine-phospho-guanosine (CpG) motif. The immunogenic compositions are suitable for stimulating an immune response against Y. pestis in a subject in need thereof. The present disclosure also relates to kits and methods using the immunogenic compositions, or two separate compositions which together comprise the antigen, the aluminum salt adjuvant, and the oligonucleotide.Type: GrantFiled: June 29, 2023Date of Patent: July 22, 2025Assignees: Dynavax Technologies Corporation, The Government of the United States, as Represented by the Secretary of the ArmyInventors: Robert S. Janssen, David Novack, Wai Kwan Chung, Andrew M. Glenn, Lucy A. Ward
-
Patent number: 12296002Abstract: The present invention relates to an immunogenic composition against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), especially to an immunogenic composition having a recombinant SARS-CoV-2 S protein and adjuvant.Type: GrantFiled: June 18, 2021Date of Patent: May 13, 2025Assignees: MEDIGEN VACCINE BIOLOGICS CORPORATION, DYNAVAX TECHNOLOGIES CORPORATIONInventors: Tsun-Yung Kuo, Charles Chen, Chung-Chin Wu, Yi-Jiun Lin, Meei-Yun Lin, Yu-Chi Wu, John Darren Campbell, Robert S. Janssen, David Novack, Robert Coffman, Paula Traquina
-
Publication number: 20240165215Abstract: The present disclosure relates to immunogenic compositions comprising at least one Yersinia pestis (Y. pestis) antigen, an aluminum salt adjuvant, and an oligonucleotide comprising an unmethylated cytidine-phospho-guanosine (CpG) motif. The immunogenic compositions are suitable for stimulating an immune response against Y. pestis in a subject in need thereof. The present disclosure also relates to kits and methods using the immunogenic compositions, or two separate compositions which together comprise the antigen, the aluminum salt adjuvant, and the oligonucleotide.Type: ApplicationFiled: June 29, 2023Publication date: May 23, 2024Applicants: Dynavax Technologies Corporation, The Government of the United States, as Represented by the Secretary of the ArmyInventors: Robert S. JANSSEN, David Novack, Wai Kwan Chung, Andrew M. Glenn, Lucy A. Ward
-
Publication number: 20230218740Abstract: The present disclosure relates to immunogenic compositions comprising a severe acute respiratory syndrome coron-avirus 2 (SARS-CoV-2) antigen, and a toll-like receptor 9 (TLR9) agonist, such as an oligonucleotide comprising an unmethylated cytidine-phospho-guanosine (CpG) motif. The immunogenic compositions are suitable for stimulating an immune response against a SARS-CoV-2 in an individual in need thereof.Type: ApplicationFiled: March 1, 2021Publication date: July 13, 2023Applicant: Dynavax Technologies CorporationInventors: John D. CAMPBELL, Robert S. JANSSEN, David NOVACK
-
Patent number: 11684669Abstract: Described herein are CpG-adjuvanted SARS-CoV-2 vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.Type: GrantFiled: September 10, 2021Date of Patent: June 27, 2023Assignees: Valneva Austria GmbH, Dynavax Technologies CorporationInventors: Andreas Meinke, Michael Möhlen, Christoph Reinisch, Robert Schlegl, Christian Taucher, John Campbell, David Novack, Robert S. Janssen, Jürgen Heindl-Wruss
-
Publication number: 20230110516Abstract: The present disclosure relates to immunogenic compositions comprising a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen, and a toll-like receptor 9 (TLR9) agonist, such as an oligonucleotide comprising an unmethylated cytidine-phospho-guanosine (CpG) motif. The immunogenic compositions are suitable for stimulating an immune response against a SARS-CoV-2 in an individual in need thereof.Type: ApplicationFiled: March 1, 2021Publication date: April 13, 2023Applicants: Dynavax Technologies Corporation, MEDIGEN VACCINE BIOLOGICS CORPORATIONInventors: John D. CAMPBELL, Robert S. JANSSEN, David NOVACK, Tsun-Yung KUO, Charles CHEN, Chung-Chin WU, Yi-Jiun LIN, Meei-Yun LIN, Yu-Chi WU
-
Publication number: 20230092650Abstract: The present disclosure relates to immunogenic compositions comprising a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen, and a toll-like receptor 9 (TLR9) agonist, such as an oligonucleotide comprising an unmethylated cytidine-phospho-guano sine (CpG) motif. The immunogenic compositions are suitable for stimulating an immune response against a SARS-CoV-2 in an individual in need thereof.Type: ApplicationFiled: March 1, 2021Publication date: March 23, 2023Applicants: Dynavax Technologies Corporation, Valneva Austria GmbHInventors: John D. Campbell, Robert S. Janssen, David Novack, Christian Taucher, Christoph Reinisch, Andreas Meinke, Michael Möhlen, Robert Schlegl, Jürgen Heindl-Wruss
-
Publication number: 20230072809Abstract: The present disclosure relates to immunogenic compositions comprising tetanus, diphtheria, and acellular pertussis (Tdap) antigens, and a toll-like receptor 9 (TLR9) agonist, such as oligonucleotide comprising an unmethylated cytidine-phospho-guanosine (CpG) motif. The immunogenic compositions may further comprise an aluminum salt adjuvant to which the Tdap antigens are adsorbed. The immunogenic compositions are suitable for active booster immunization against tetanus, diphtheria, and pertussis in an individual in need thereof.Type: ApplicationFiled: March 9, 2021Publication date: March 9, 2023Applicants: Dynavax Technologies Corporation, Serum Institute of India Private LimitedInventors: John D. CAMPBELL, Robert L. COFFMAN, Randall N. HYER, Robert S. JANSSEN, David NOVACK, Martin GOHLKE, Maureen URBAN, Sunil GAIROLA, Umesh SHALLIGRAM, Manish GAUTUM, Harish RAO
-
Publication number: 20230061403Abstract: The present disclosure relates to immunogenic compositions comprising a varicella zoster vims (VZV) glycoprotein E antigen and a toll-like receptor 9 (TLR9) agonist, such as an oligonucleotide comprising an unmethylated cytidine-phospho-guanosine (CpG) motif. The immunogenic compositions are suitable for stimulating an immune response against VZV in an individual in need thereof.Type: ApplicationFiled: March 9, 2021Publication date: March 2, 2023Applicant: Dynavax Technologies CorporationInventors: John D. CAMPBELL, Randall N. HYER, Robert S. JANSSEN, David NOVACK
-
Publication number: 20230038284Abstract: Described herein are CpG-adjuvanted SARS-CoV-2 vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.Type: ApplicationFiled: September 10, 2021Publication date: February 9, 2023Applicants: Valneva Austria GmbH, Dynavax Technologies CorporationInventors: Andreas Meinke, Michael Möhlen, Christoph Reinisch, Robert Schlegl, Christian Taucher, John Campbell, David Novack, Robert S. Janssen
-
Publication number: 20210308257Abstract: The present invention relates to an immunogenic composition against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), especially to an immunogenic composition having a recombinant SARS-CoV-2 S protein and adjuvant.Type: ApplicationFiled: June 18, 2021Publication date: October 7, 2021Inventors: Tsun-Yung KUO, Charles CHEN, Chung-Chin WU, Yi-Jiun LIN, Meei-Yun Lin, Yu-Chi WU, John Darren CAMPBELL, Robert S. JANSSEN, David NOVACK
-
Publication number: 20070234499Abstract: A windshield washer control system comprising a wiper device; a motor connected to the wiper device, the motor being in operative connection with a controller, the controller including a timer; a pump selectively operated by the controller; and a sprayer for dispensing fluid.Type: ApplicationFiled: April 6, 2006Publication date: October 11, 2007Inventors: Harold Thibodeau, James Burcar, David Novack